BAY 2666605
CAS No. 2275774-60-0
BAY 2666605( —— )
Catalog No. M28912 CAS No. 2275774-60-0
BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 258 | In Stock |
|
| 5MG | 235 | In Stock |
|
| 10MG | 376 | In Stock |
|
| 25MG | 828 | In Stock |
|
| 50MG | 1293 | In Stock |
|
| 100MG | 2074 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBAY 2666605
-
NoteResearch use only, not for human use.
-
Brief DescriptionBAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.
-
DescriptionBAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.(In Vitro):BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer.(In Vivo):In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorWnt
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2275774-60-0
-
Formula Weight352.28
-
Molecular FormulaC17H12F4N2O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 250 mg/mL (709.66 mM)
-
SMILESC[C@@H]1OC(=O)NN=C1C1=CC=C(C2=CC=C(F)C=C2)C(=C1)C(F)(F)F
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Basu D, et al. Identification, mechanism of action, and antitumor activity of a small molecule inhibitor of hippo, TGF-β, and Wnt signaling pathways. Mol Cancer Ther. 2014 Jun;13(6):1457-67.
molnova catalog
related products
-
CDP-840 hydrochlorid...
CDP-840 (CDP840;L-765527) is a potent and selective PDE4 inhibitor with IC50 of 4-45 nM.
-
Imazodan
Imazodan, a small molecule compound with positive inotropic activity, is a selective type III phosphodiesterase inhibitor and can be used to study heart failure.
-
OPC18750 HCl
OPC18750 HCl is a potential phosphodiesterase inhibitor with positive inotropic effects that can be used to study asthma, cancer, diabetes, and psychiatric disorders.
Cart
sales@molnova.com